Suchergebnisse

Ironwood Pharmaceuticals (IRWD) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of $0.02. This compares to earnings of $0.02 per share a year ago. These figures

Ironwood Pharmaceuticals IRWD reported an adjusted loss of 1 cent per share for the fourth quarter of 2025, against the Zacks Consensus Estimate of earnings of 2 cents. The company had reported

Ironwood Pharmaceuticals’ IRWD sole marketed product, Linzess (linaclotide), is approved for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients aged

Ironwood Pharmaceuticals IRWD and Puma Biotechnology PBYI are small-cap biotech firms that depend largely on the successful commercialization of a single key drug while trying to broaden their